Peter Flynn PhD

Peter Flynn was Chief Technology Officer Peter Flynn has over 18 years of biotechnology industry experience. Prior to joining Artiva as CTO, he was EVP of Orexigen Therapeutics where he led clinical development, medical affairs, regulatory affairs, and safety functions. Prior to Orexigen, Pete was SVP, Early Program Development at Fate Therapeutics where he was responsible for the regenerative medicine programs and development of the iPSC platform. Prior to Fate, he was Vice President of Research at Ren Pharmaceuticals. Pete started his industry career as one of the first employees at the antibody therapeutics company KaloBios Pharmaceuticals, whereas the head of biochemistry he helped build both the platform technology and monoclonal therapeutic pipeline. Pete holds a BSc in Molecular Biology from University College London, a PhD in Biochemistry from Imperial Cancer Research Fund (CRUK) and was a postdoctoral fellow at the University of California, San Francisco Cancer Center.